Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Osteosarcoma

High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma

Bone Marrow Transplantation volume 27, pages 933–937 (2001)Cite this article

Abstract

In this report, we describe our experience with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in 15 children with relapsed osteosarcoma who were treated by members of the Cooperative Osteosarcoma Study Group. Eight patients received HDC after the first relapse, six patients after the second relapse and one after the sixth relapse. Thirteen patients underwent HDC and ASCT in complete remission and two patients had macroscopic tumor residues. Seven patients received HDC based on melphalan and etoposide. Four of these patients were treated with additional carboplatinum. Two patients received carboplatinum, etoposide, and thiotepa or cyclophosphamide. In six patients double HDC was performed. In all six of these, the first HDC consisted of thiotepa/ cyclophosphamide. The second regimens included melphalan/etposide (two patients), melphalan/etposide/ carboplatinum (one patient), and melphalan/busulfan (one patient). Three of the 15 patients died of toxic complications. Eight patients developed further relapses, two patients showed persistent disease, and two patients are presently in continuous complete remission. The probability of relapse-free survival was 0.20 ± 0.12 within a median follow-up (MFU) of 8 months and the probability of overall survival was 0.29 ± 0.12 after a MFU of 16 months. In conclusion, utilization of HDC and ASCT in this patient group did not significantly improve the treatment outcome compared to conventional relapse therapy. Bone Marrow Transplantation (2001) 27, 933–937.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Fuchs N, Bielack S, Epler D et al. Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs Ann Oncol 1998 9: 893–899

    Article  CAS  PubMed  Google Scholar 

  2. Winkler K, Bielack SS, Delling G et al. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS) Cancer Treat Res 1993 62: 269–277

    Article  CAS  PubMed  Google Scholar 

  3. Atra A, Pinkerton R . Autologous stem cell transplantation in solid tumours of childhood Ann Med 1996 28: 159–164

    Article  CAS  PubMed  Google Scholar 

  4. Perentesis JP, Katsanis E, DeFor TE et al. Autologous stem cell transplantation for high-risk pediatric solid tumors Bone Marrow Transplant 1999 24: 609–615

    Article  CAS  PubMed  Google Scholar 

  5. Miniero R, Brach del Prever A, Vassallo E et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma Bone Marrow Transplant 1998 22: (Suppl. 5) 37–40

    Google Scholar 

  6. Chan KW, Petropoulos D, Choroszy M et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric tumors Bone Marrow Transplant 1997 20: 1039–1043

    Article  CAS  PubMed  Google Scholar 

  7. Lazarus HM, Gray R, Ciobanu N et al. Phase I trial of high dose melphalan, high dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study Bone Marrow Transplant 1994 14: 443–448

    CAS  PubMed  Google Scholar 

  8. Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma J Clin Oncol 1998 16: 1697–1706

    Article  CAS  PubMed  Google Scholar 

  9. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies Bone Marrow Transplant 1994 14: 813–819

    CAS  PubMed  Google Scholar 

  10. Diaz, Vicent MG, Madero L . High dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors Bone Marrow Transplant 1999 24: 1157–1159

    Article  CAS  PubMed  Google Scholar 

  11. Bielack S, Kempf-Bielack B, Schwenzer D et al. Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the cooperative osteosarcoma study group COSS of 925 patients Klin Padiatr 1999 211: 260–270

    Article  CAS  PubMed  Google Scholar 

  12. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group New Engl J Med 1999 341: 1165–1173

    Article  CAS  PubMed  Google Scholar 

  13. Frohlich B, Ahrens S, Burdach S et al. High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS Klin Padiatr 1999 211: 284–290

    Article  CAS  PubMed  Google Scholar 

  14. Lucidarme N, Valteau-Couanet D, Oberlin O et al. Phase II study of high dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors Bone Marrow Transplant 1998 22: 535–540

    Article  CAS  PubMed  Google Scholar 

  15. Colombat P, Biron P, Coze C et al. Failure of high-dose alkylating agents in osteosarcoma Bone Marrow Transplant 1994 14: 665–666

    CAS  PubMed  Google Scholar 

  16. Saeter G, Hoie J, Stenwig AE et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival Cancer 1995 75: 1084–1093

    Article  CAS  PubMed  Google Scholar 

  17. Fagioli F, Brach del Prever A, Tienghi A et al. High dose chemotherapy (HD-CT) followed by peripheral blood stem cell (PBSC) rescue in relapsed osteosarcoma Bone Marrow Transplant 2000 25 (Suppl. 1): 72 (Abstr. 182)

    Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the physicians, nurses, data-managers, and support staff of the collaborating centers for their active participation. The patients included in this report were treated at the following institutions: Children's University Hospital Frankfurt/M, Children's University Hospital Göttingen, Children's University Hospital Heidelberg, University of Jena, Department of Pediatrics, Children's University Hospital Lübeck, University of Münster, Department of Pediatric Hematology/ Oncology, Germany, St Anna Children's Hospital, Vienna, Austria.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Jena, Germany

    A Sauerbrey & F Zintl

  2. Department of Pediatric Hematology/Oncology, Cooperative Osteosarcoma Study Group, University of Münster, Germany

    S Bielack, B Kempf-Bielack & M Paulussen

  3. St. Anna Children's Hospital, Vienna, Austria

    A Zoubek

Authors
  1. A Sauerbrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bielack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Kempf-Bielack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Zoubek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Paulussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Zintl
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Cooperative Osteosarcoma Study Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sauerbrey, A., Bielack, S., Kempf-Bielack, B. et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 27, 933–937 (2001). https://doi.org/10.1038/sj.bmt.1703023

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703023

Keywords

This article is cited by

Search

Advanced search

Quick links